Drugs in Dev.
Infections and Infectious Diseases
Phase I/ Phase II
Netherlands 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
Details : ISA104 is designed to developed using Synthetic Long Peptide (SLP®) technology and create a strong and specific immune response against HBV, with the aim to functionally cure chronically infected patients.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanovac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Dutch Leiden University Medical Center
Deal Size : Undisclosed
Deal Type : Partnership
Details : This new vaccine, NANOVAC, is based on microscopic soluble nano-spheres, containing synthetic mini proteins that, when administered as a nasal spray, directly protects the upper respiratory tract including nasal passages and throat (mucosa) before the vi...
Product Name : Nanovac
Product Type : Vaccine
Upfront Cash : Undisclosed
January 05, 2022
Lead Product(s) : Nanovac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Dutch Leiden University Medical Center
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University’S Jenner Institute
Deal Size : Undisclosed
Deal Type : Collaboration
HALIX Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine
Details : Under the collaboration, Halix will utilise its brand new state-of-the-art GMP facilities with capacity up to 1,000 L SUB scale, supporting the manufacture of ChAdOx1 nCoV-19 clinical trial material.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 15, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University’S Jenner Institute
Deal Size : Undisclosed
Deal Type : Collaboration
